P50 Dose-escalation study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type K-ras

J.Zhou; L.Shen; J.Zheng

首页> 外文期刊>European Journal of Cancer Supplements >P50 Dose-escalation study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type K-ras

【24h】

P50 Dose-escalation study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type K-ras

机译：尼莫妥珠单抗加伊立替康作为野生型K-ras转移性结直肠癌二线治疗的P50剂量递增研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2011年第1期|共1页
作者
J.Zhou; L.Shen; J.Zheng;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer [J] . CarratoA., GómezA., EscuderoP., Clinical & translational oncology : . 2013,第9期

机译：每三周使用Panitumumab和irinotecan是一种有效且方便的方案，用于野生型K-RAS转移性结直肠癌患者的二线治疗
2. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial [J] . Yuankai Shi, Jin Li, Jianming Xu, Cancer Communications . 2019,第1期

机译：CMAB009加上Irinotecan与Irinotecan-ock氟嘧啶和Oxaliplatin失败后的二线治疗，在KRAS野生型转移性结肠直肠癌患者中：有前景，开放标签，随机，第三阶段试验的有前景的发现
3. Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study) [J] . Nagata Naoki, Maeda Hiromichi, Ishibashi Keiichiro, Medical oncology . 2019,第6期

机译：克拉野生型转移性结直肠癌（太平洋研究）患者中二线Panitumumab和Irinotecan的二中心开放式随机阶段II研究
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. Use and outcomes of newer chemotherapeutic agents in colorectal cancer patients using Irinotecan as a case study. [D] . Obeidat, Nour A. 2008

机译：以伊立替康为例的结直肠癌患者中新型化疗药物的使用和结果。
6. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective open-label randomized phase III trial [O] . Yuankai Shi, Jin Li, Jianming Xu, 2019

机译：CMAB009加伊立替康与仅依立替康作为氟嘧啶和奥沙利铂治疗KRAS野生型转移性结直肠癌患者的二线治疗：前瞻性开放标签随机III期试验的有希望的发现
7. P50 Dose–escalation study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type K-ras [O] . Zhou J., Shen L., Zheng J. 2011

机译：P50尼莫妥珠单抗联合伊立替康的剂量递增研究作为野生型K-ras转移性结直肠癌的二线治疗

P50 Dose-escalation study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type K-ras

著录项

相似文献

相关主题

期刊订阅